A Randomized Trial of Initiation of Chronic Noninvasive Mechanical Ventilation at Home vs In-Hospital in Patients With Neuromuscular Disease and Thoracic Cage Disorder: The Dutch Homerun Trial

• Published in: Chest Vol. 158; no. 6; pp. 2493 - 2501
• Main Authors: van den Biggelaar, Ries J M, Hazenberg, Anda, Cobben, Nicolle A M, Gaytant, Michael A, Vermeulen, Karin M, Wijkstra, Peter J
• Format: Journal Article
• Language: English
• Published: United States 01.12.2020
• Subjects: telemedicine; neuromuscular disease; thoracic cage abnormality; noninvasive ventilation
• ISSN: 1931-3543
• DOI: 10.1016/j.chest.2020.07.007

There is an increasing demand for home mechanical ventilation (HMV) in patients with chronic respiratory insufficiency. At present, noninvasive ventilation is exclusively initiated in a clinical setting at all four centers for HMV in the Netherlands. In addition to its high societal costs and patient discomfort, commencing HMV is often delayed because of a lack of hospital bed capacity. Is HMV initiation at home, using a telemonitoring approach, noninferior to in-hospital initiation in a nationwide study? We conducted a nationwide, randomized controlled noninferiority trial, in which every HMV center recruited 24 patients (home [n = 12] vs hospital [n = 12]) with a neuromuscular disease or thoracic cage disorder, all with an indication to start HMV. Change in arterial CO (Paco ) over a 6-month period was considered the primary outcome, and quality of life and costs were assessed as secondary outcomes. A total of 96 patients were randomized, most of them diagnosed with neuromuscular disease. We found a significant improvement in Paco within both groups (home: from 6.1 to 5.6 kPa [P < .01]; hospital: from 6.3 to 5.6 kPa [P < .01]), with no significant differences between groups. Health-related quality of life showed significant improvement on various subscales; however, no significant differences were observed between the home and hospital groups. From a societal perspective, a cost reduction of more than €3,200 ($3,793) per patient was evident in the home group. This nationwide, multicenter study shows that HMV initiation at home is noninferior to hospital initiation, as it shows the same improvement in gas exchange and health-related quality of life. In fact, from a patient's perspective, it might even be a more attractive approach. In addition, starting at home saves over €3,200 ($3,793) per patient over a 6-month period. ClinicalTrials.gov; No.: NCT03203577; URL: www.clinicaltrials.gov.